Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference [Yahoo! Finance]
Intensity Therapeutics, Inc. (INTS)
Company Research
Source: Yahoo! Finance
the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that Lewis H. Bender , President and Chief Executive Officer, will present a company overview at the 2024 BIO CEO & Investor Conference on Monday, February 26, 2024 , at the New York Marriott Marquis at 11:45am ET in the Uris Room. Mr. Bender will also host in-person one-on-one meetings during the event. For more information about the 2024 BIO CEO & Investor Conference, please visit https://bcic.bio.org/ About Intensity Therapeutics Intensity Therapeutics is a late-stage clinical biotechnology company that applies novel engineered chemistry to turn "cold" tumors "hot" by enabling its aqueous cytotoxic-containing drug product, INT230-6, to mix and saturate the dense, high-fat pressurized environment of the tumor. As a result of the saturation, Intensity's clinical trials have demonstrated the abilit
Show less
Read more
Impact Snapshot
Event Time:
INTS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INTS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INTS alerts
High impacting Intensity Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
INTS
News
- Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug CandidatePR Newswire
- Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdatePR Newswire
- Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024 [Yahoo! Finance]Yahoo! Finance
- Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024PR Newswire
INTS
Sec Filings
- 5/10/24 - Form 8-K
- 5/9/24 - Form 8-K
- 5/9/24 - Form 10-Q
- INTS's page on the SEC website